US EditionEU Approves New Alzheimer’s Drug Kisunla
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
EU Approves New Alzheimer’s Drug Kisunla
The European Commission has formally approved Kisunla, a new Alzheimer’s treatment developed by Eli Lilly, for sale across the European market. The decision follows a July recommendation from the European Medicines Agency. Kisunla is the second drug of its kind to receive EU authorization and contains an antibody shown to slow disease progression in patients at an early stage of Alzheimer’s.
The European Commission has approved the sale and use of the drug Kisunla, which can slow the progression of Alzheimer's disease. Alzheimer's and other dementias are considered one of the greatest health threats of our time. EPA / CRISTOBAL HERRERA-ULASHKEVICH Kisunla, developed and manufactured by the US pharmaceutical company Eli Lilly, was approved by the European Medicines Agency in July. Kisunla is the second drug of its kind to be approved…
Alzheimer's drug approved in EU The formal approval comes after the EU Medicines Agency EMA gave its blessing in July. This means the company can now start selling the drug on the European market. Kisunla is the second drug of its kind to be approved in the EU. It contains an antibody that can partially slow the progression of patients who are in the early stages of the disease. It is approved for the treatment of patients with mild cognitive i…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
